More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
2022 in Review: Alcon Makes Big Push into Pharma with Three Ophthalmic Acquisitions
Author: Chelsea Jones, MBA
Three of the 19 ophthalmic acquisitions in 2022 were completed by Alcon; the purchases demonstrate the company’s plan to expand its presence in the ophthalmic pharmaceuti-cals market. In 2022, the company closed its acquisitions of Ivantis in January, Kala’s Eysuvis and Inveltys in July, and Aerie Pharmaceuticals in November. These transactions, along with the 2021 acquisition of the exclusive US commercialization rights for Simbrinza from Novartis, position Alcon for strong growth in the oph...
Purchasing one of the following products will open up access to this article's content, which is also available in each comprehensive report/subscription.
Recommended Products
This website uses cookies to ensure you get the best experience. By continuing to use our website, you consent to our use of cookies.